Ligand Pharmaceuticals stockholders approve stock plan amendment at annual meeting

Filed June 9, 2026 · Period ending June 5, 2026 · ~1 min read

Key Changes

• medium

  Stockholders approved amendment and restatement of the 2002 Stock Incentive Plan, allowing continued equity compensation grants under updated terms with 95% support.

  Item 5.07 verify on EDGAR →
• low

  All eight director nominees elected to one-year terms expiring 2027, including Jason Aryeh, Todd Davis, Nancy Gray, Jason Haas, John Kozarich, John LaMattina, Stephen Sabba, and Martine Zimmermann.

  Item 5.07 verify on EDGAR →
• low

  Ernst & Young LLP ratified as independent auditor for fiscal 2026 with 99% approval, continuing the firm's engagement.

  Item 5.07 verify on EDGAR →